Business
MedX Announces Application for Final Extension of Non-Brokered Private Placement
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: M...
About this update from Medx Health Corp.
MedX Announces Application for Final Extension of Non-Brokered Private Placement .bwalignc { text-align: center; list-style-position: inside } MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX ) is pleased to announce that, further to its Press Release dated March 16, 2026, when it announced application for an extension of time within which to effect further closings of the Non-brokered Private Placement to accredited investors of Series IV Convertible Loan Notes (“ Series IV Notes ”) originally announced in its Press Release dated February 2, 2026, and the First Closing which was announced in its Press Release of February 27, 2026, it has made application to the TSX Venture Exchange for a final extension of 30 days to May 15, 2026, within which to effect further closings on this Private Placement of Series IV Convertible Loan Notes (“ Series IV Notes ”). The Initial Closing, effective February 27, 2026, comprised the issuance of $2,700,000 of Series IV Notes. With the proposed extension of the final date for this Placement, it is anticipated that further Closings will take place, for up to a maximum of a further $2,300,000 of Series IV Notes. The Series IV Notes bear interest at 6% per year, payable Quarterly, and mature on December 31, 2028 (the “ Maturity Date ”). The Series IV Notes may be converted, at the option of the Holder, into units at $0.10 per unit (“ Unit ”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.125, exercisable for a period expiring on the Maturity Date. Holders of Series I Convertible Loan Notes (“ Series I Notes ”) who wish to do so, will be able to surrender their Series I Notes by way of subscription for Series IV Notes. The Series I Notes matured on December 31, 2025, and their terms were similar to the Series IV Notes except that the conversion price was $0.14 and the Warrant exercise price was $0.20. Qualified agents will receive a cash commission equal to 6% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent’s warrants (ȁ...